RxDoctor Payments Data

Jason Stewart

Family · Cordova, TNNPI 1427480565

Payments from drug & device makers

$7,757in general payments, 2019–2025

Across 434 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • GSK$750
  • AbbVie$634
  • Amgen$631
  • Lilly USA, LLC$501
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$7,757100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,757 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$77,842
Medicare patients
215
Services billed
2,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide24$25,600
OzempicSemaglutide17$17,786
JanumetSitagliptin Phos/Metformin Hcl14$16,342
EliquisApixaban23$14,148
ArexvyRsvpref3 Antigen/As01e/Pf17$5,300
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,434
Atorvastatin Calcium181$1,652
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide25$1,174
Albuterol Sulfate HfaAlbuterol Sulfate38$1,062
Amlodipine Besylate133$827
Losartan Potassium59$728
Fenofibrate18$649
Levothyroxine Sodium63$611
Rosuvastatin Calcium56$588
Omeprazole52$526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$501$25,60024 claims
Novo NordiskOzempic$1,856$17,78617 claims
MerckJanumet$201$16,34214 claims
PfizerEliquis$144$14,14823 claims
GSKArexvy, Shingrix$750$7,73428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Cordova

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →